Medical Oncologist
Liver cancer treatment
Sorafenib With TACE: — What Each Treatment Contributes
Being prescribed two treatments at once can be confusing. TACE targets the tumour's blood supply directly inside the liver. Sorafenib acts on the signals the tumour releases to rebuild after local treatment. Understanding both helps you ask the right questions at your next appointment.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Two mechanisms, one goal — TACE cuts off the tumour's blood supply locally. Sorafenib blocks the signals that would allow it to regrow.
- Sequencing matters — Sorafenib is usually started after the liver has recovered from TACE, not at the same time.
- Different side effects at different times — TACE causes fever and liver pain in the days after the procedure. Sorafenib's main effect — the hand-foot skin reaction — appears during ongoing treatment.
- Evidence is still developing — Clinical trials have produced mixed results for this combination. Your oncologist has weighed the evidence for your specific situation.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
TACE delivers chemotherapy directly into the artery feeding the liver tumour and then blocks that artery. Sorafenib is added to target new blood vessel growth that TACE can trigger as the tumour tries to rebuild its supply. Together, they attack the tumour locally and aim to limit its recovery.
What does TACE actually do to the tumour?
TACE stands for transarterial chemoembolisation. A radiologist threads a thin catheter through a blood vessel, usually in the groin, into the hepatic artery — the main blood supply to liver tumours.
Chemotherapy is injected directly into the artery feeding the tumour. Then that artery is blocked using small particles. The tumour receives a concentrated dose of chemotherapy and loses its blood supply at the same time.
This double effect — local chemotherapy plus cutting off blood flow — is what makes TACE useful for liver tumours that cannot be removed surgically. Because the drug goes straight to the tumour, the rest of the body receives much less of it than with standard intravenous chemotherapy.
Why is sorafenib added to a local liver treatment?
When a tumour's blood supply is cut off, it releases chemical signals to grow new blood vessels. One of the most important of these is a protein called VEGF. This is a survival response — the tumour is trying to rebuild what was destroyed.
Sorafenib blocks the receptors that respond to VEGF. It also acts on signalling pathways inside tumour cells that drive growth. Its role in the combination is to limit the tumour's ability to recover and re-vascularise after TACE.
TACE works inside the liver. Sorafenib acts throughout the body. The rationale for combining them is that each targets what the other cannot reach.
How is the course of treatment organised?
Staging and liver function review
Before anything is planned, your team will assess the extent of the disease, your liver function score, and the state of the portal vein. These determine whether TACE is safe and whether the liver can tolerate sorafenib alongside it.
TACE procedure
The procedure is done by an interventional radiologist, usually as a day admission or short inpatient stay. You will be given sedation or anaesthesia. The catheter is positioned in the hepatic artery under imaging guidance before the drug and blocking particles are delivered.
Recovery from TACE
Most people experience post-embolisation syndrome — fever, aching pain over the liver, and nausea — for a few days after the procedure. Your team expects this. Rest and regular pain relief are the usual management. You will be reviewed after a few weeks.
Starting sorafenib
Sorafenib is started after recovery from TACE is confirmed and liver function has stabilised. The timing is decided by your oncologist based on how the liver has responded. Do not start sorafenib after TACE unless your team has specifically instructed you to, even if you already have a prescription.
Follow-up imaging
CT or MRI of the liver is done at intervals to assess how the tumour has responded. Sorafenib also requires regular blood pressure monitoring and review of skin and gut side effects at each visit.
Decision on further TACE
If the tumour has responded, further TACE sessions may be planned. If the disease has progressed despite treatment, your team will discuss what comes next.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What do the medical terms your team is using actually mean?
- TACE
- Transarterial chemoembolisation. A procedure that delivers chemotherapy directly into the tumour's blood supply, then blocks that supply.
- Hepatic artery
- The main artery supplying the liver. Liver tumours draw most of their blood from this artery, which is why TACE targets it.
- Embolisation
- Deliberately blocking a blood vessel. In TACE, small particles or a gel are used to cut off blood flow to the tumour.
- VEGF
- Vascular endothelial growth factor. A protein the tumour releases to trigger new blood vessel growth. Sorafenib blocks the receptors that respond to it.
- Post-embolisation syndrome
- Expected side effects after TACE — fever, liver area pain, nausea — caused by the dying tumour tissue. It is expected and does not mean something has gone wrong.
- Child-Pugh score
- A measure of liver function using blood results and clinical signs. A poor score can mean TACE or sorafenib carries too high a risk for your liver.
What side effects should you expect from the two treatments?
TACE and sorafenib cause different side effects at different points in treatment, so you are rarely managing both sets at the same time.
TACE causes post-embolisation syndrome in most people — fever, aching pain over the liver, and nausea for a few days after the procedure. This is expected and managed with pain relief and rest. It is not a sign of a complication.
Sorafenib most commonly causes a hand-foot skin reaction — the palms and soles become tender, red, and may peel or blister in pressure areas. Tell your team as soon as you notice any redness or soreness, before blisters appear, because dose adjustment is much easier at that stage. Fatigue, diarrhoea, and raised blood pressure are also common with sorafenib and are reviewed at each visit.
Did you know?
Cutting off a tumour's blood supply with TACE causes the tumour to release elevated levels of VEGF — the protein that signals new blood vessel growth. This is a predictable tumour survival response, not a failure of TACE. Sorafenib is added specifically to block the growth signal that the local treatment itself triggers.
Source: ESMO Clinical Practice Guidelines: Hepatocellular Carcinoma
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Will I need more than one TACE session?
Often yes. TACE is typically repeated if the first session produces a response and the liver can tolerate a further procedure. How many sessions are appropriate depends on how the tumour has responded on follow-up imaging, how well the liver is functioning, and whether the disease has progressed. Your team will review the imaging before deciding whether another session is worthwhile.
How soon after TACE does sorafenib start?
The timing varies and is decided by your oncologist based on how your liver has recovered. Liver function tests need to show the liver has stabilised before sorafenib is safe to add. Starting too soon carries a higher risk of liver-related side effects from the combination. Do not start sorafenib after TACE unless your team has specifically told you to, even if you already have a prescription for it.
What is the hand-foot skin reaction and what should I do about it?
The hand-foot skin reaction is the most distinctive side effect of sorafenib. The palms and soles become tender and red, often in pressure areas, and the skin can blister or break down if it is not managed early. Tell your team as soon as you notice any redness or soreness — dose adjustment or a short break is much easier to arrange before the skin breaks down. Thick moisturiser and soft, well-fitting footwear can reduce friction in early stages. Your team may refer you to a dermatologist if the reaction becomes severe.
Does adding sorafenib to TACE work better than TACE alone?
The evidence is genuinely mixed, and it is worth knowing this. Some trials — including the TACTICS trial published in Lancet Gastroenterology and Hepatology — showed the combination improved the time before the disease progressed. Others, including the SPACE trial, did not show a significant benefit on the same measure. ESMO and the BCLC group acknowledge the evidence is still developing. Your oncologist has considered this evidence alongside your specific tumour characteristics and liver function when recommending the combination.
What if my liver function is not good enough for TACE?
If liver function is too poor, TACE carries a risk of causing liver failure in the tissue surrounding the tumour. In that situation, your team may recommend sorafenib on its own as the primary systemic treatment, or discuss other options depending on your cancer stage and overall fitness. The decision rests on your Child-Pugh score and the extent of underlying liver disease. A second opinion from a hepatologist or a specialist liver multidisciplinary team can sometimes help clarify whether TACE remains an option for you.
Can sorafenib be given without TACE?
Yes. Sorafenib was approved for hepatocellular carcinoma as a systemic treatment in its own right, based on the SHARP trial, which showed improved overall survival in patients with advanced disease compared with placebo. TACE is a local procedure suited to tumours confined to the liver without major involvement of the portal vein. If the disease is more advanced, or if TACE is not safe for your liver, sorafenib alone may be the recommended approach. Your oncologist will explain what drives the decision for your specific situation.